Fighting Cancer ... with Science

Sickle Cells Combined with Vascular Disruption Eradicate Lung Tumors on Cover of Journal of Clinical Investigation Insight, April 3, 2019

JCI insight Cover page.pptx
Microsoft Power Point presentation [5.3 MB]
Journal of Clinical Investigation Insigh[...]
Adobe Acrobat document [865.1 KB]

Sickle Cells Produce Immune Modulators and Cytotoxics, American Journal of Hematology, October 20, 2017

American J Hematol - 2017 - Sun - Sickle[...]
Adobe Acrobat document [822.2 KB]

Sickle Cells Abolish Melanoma Tumorigenesis and Augment the Tumoricidal Effect of Oncolytic Virus, Frontiers in Oncology. July 8, 2016

Frontiers in Oncology.pdf
Adobe Acrobat document [1.5 MB]

Sickle Cells Combined with Vascular Disruption Eradicate Lung Tumors

Issued US patent on Sickel Cells Combine[...]
Adobe Acrobat document [6.1 MB]

October 10, 2013
“Programmed Sickle Cells Augment Delivery of Cytotoxics to Tumors"...Data Highlighted on Cover of
Journal of Controlled Release (impact factor:8) with Editorial by Editor Professor K. Kwon of Purdue University

Drug loaded SSRBCs.pdf
Drug loaded SSRBCs.pdf
Adobe Acrobat document [1.5 MB]
JCR Cover story - 2013 (2).pdf
JCR Cover story - 2013 (2).pdf
Adobe Acrobat document [279.8 KB]

Dr. Terman Talks About “Drug-Loaded Sickle Cells in Cancer Treatment” with Joan Hamburg on WOR Radio, New York

 January 9. 2013

"Sickle Cells Target Cytotoxics to Hypoxic Tumor Micorvessels and Potentiate a Tumoricidal Response" published in PLOS ONE (Impact factor:14)

Sickle Erythrocytes Target Cytotoxics to Hypoxic Tumor Microvessels and Potentiate a Tumoricidal Response
Terman et al., PLOS ONE.pdf
Adobe Acrobat document [2.0 MB]

CBS TV News: Dr.David  Terman discusses  Sickle Cells for Treatment for Drug Resistant Breast Cancer with

Dr. Max Gomez below

BBC Coverage 


NCI Cancer Center Coverage


Video Demonstration of a sickle cells in action against a highly drug resistant  breast tumor.  After injection of labelled sickle cells (SRBCs) the SSRBCs stick to tumor blood vessel walls where they cluster and block blood flow. In contrast, normal red blood cells (NRBCs) pass freely through the tumor blood vessels without sticking or blocking blood flow.

Sickle Cells Target  Drug Resistant Breast Cancer:

Krista Hoff discusses Terman et al.,  paper in  PLOS ONE 2013  showing sickle cells targeting and killing hypoxic niches within drug resistant 4T1 mammary carcinoma in mice.

About Azore, Inc.

Azore, Inc. is a non-profit corporation devoted to developing novel drugs and drug vehicles for treatment of cancer. These efforts are supported by a raft of peer- reviewed publications and worldwide patents/patent applications.


The research team is led by David S. Terman, MD, an emeritus member of the American Society of Clinical Investigation (academia's physician-scientist honor society), former Professor  of Medicine, Microbiology and Immunology and Founding Director of Cancer Biology Program at Baylor College of Medicine. He is currently Adjunct Professor of Biochemistry and Molecular Biology at UAB in Birmingham. Dr. Terman is recipient of the Alfred P. Nielson Lifetime Achievement Award from Marqis Who's Who in 2020

As seen in the Monterey Herald

Cancer researcher David S. Terman stands among piles of research and patent paperwork in his home office in Pebble Beach on Friday. Terman runs the Azore, Inc. in Carmel. (DAVID ROYAL/The Herald)